Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.5909
Abstract: Importance Tisagenlecleucel, a chimeric antigen receptor T-cell therapy for relapsed or refractory pediatric acute lymphoblastic leukemia, has been approved for use in multiple jurisdictions. The public list price is US $475 000, or more than CaD… read more here.
Keywords: acute lymphoblastic; standard care; tisagenlecleucel; cost ... See more keywords
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2021.06.011
Abstract: PURPOSE To assess the cost-effectiveness and cost-effective price of tisagenlecleucel, a novel, effective chimeric antigen receptor T-cell therapy, versus salvage chemotherapy (SC) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)… read more here.
Keywords: lymphoma; cell; treatment; cost effective ... See more keywords
Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Hematology and Oncology"
DOI: 10.1080/08880018.2022.2035864
Abstract: Abstract Recipients of anti-CD19 targeted therapies such as chimeric antigen receptor (CAR)-T cell are considered at high risk for complicated Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection due to prolonged B cell aplasia and immunosuppression.… read more here.
Keywords: cell; tisagenlecleucel; immune responses; patient ... See more keywords
The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2019-116
Abstract: Tisagenlecleucel has an acceptable safety profile and showed preliminary evidence of CNS efficacy. read more here.
Keywords: safe secondary; cns; car therapy; tisagenlecleucel ... See more keywords
Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Pharmacotherapy"
DOI: 10.1177/1060028020948165
Abstract: Objective To evaluate the current literature for tisagenlecleucel in the treatment of relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Data Sources A literature search of PubMed (inception to June 18, 2020) and ClinicalTrials.gov was conducted… read more here.
Keywords: literature; lymphoblastic leukemia; acute lymphoblastic; tisagenlecleucel ... See more keywords
HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136340
Abstract: Background: Tisagenlecleucel is an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy approved for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma.… read more here.
Keywords: loss cell; reinfusion; efficacy; cell aplasia ... See more keywords
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003092
Abstract: Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with… read more here.
Keywords: real world; lymphoblastic leukemia; non hodgkin; acute lymphoblastic ... See more keywords
Tisagenlecleucel Immunogenicity in Relapsed/Refractory Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003844
Abstract: Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric antigen receptor (CAR) contains a… read more here.
Keywords: relapsed refractory; acute lymphoblastic; mcar19 antibodies; tisagenlecleucel ... See more keywords
Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020004045
Abstract: In the absence of head-to-head trials, an indirect-treatment comparison can estimate the treatment effect of tisagenlecleucel in comparison with blinatumomab on rates of complete remission (CR) and overall survival (OS) in patients with relapsed or… read more here.
Keywords: refractory acute; treatment; blinatumomab; lymphoblastic leukemia ... See more keywords
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007057
Abstract: The cost and toxicities of chimeric antigen receptor (CAR)-T cells require efforts to identify the patients most likely to respond. We determined whether the quality of T lymphocytes at the time of apheresis influenced the… read more here.
Keywords: clinical response; cell; cell lymphoma; tisagenlecleucel ... See more keywords
Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Drugs of today"
DOI: 10.1358/dot.2017.53.11.2725754
Abstract: On August 30, 2017, the U.S. Food and Drug Administration (FDA) approved Novartis' tisagenlecleucel (CTL-019, Kymriah), which is a synthetic bioimmune product of anti-CD19 chimeric antigen receptor (CAR) T cells, for the treatment of relapsed/refractory… read more here.
Keywords: cell therapy; treatment; anti cd19; tisagenlecleucel ... See more keywords